Answers are grounded in this paper and cite their sources.
Despite considerable intervention costs, the lower production loss resulted in I-MORE being cost-effective when compared to O-ACT. Based on economic arguments, I-MORE should be implemented as a treatment alternative for individuals on long-term sick leave. However, more research on subgroup effects and further follow-up of participants' permanent disability pension awards are warranted.
No takes yet. Share an insight, caveat, or question.
Aasdahl et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: